First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer: Mature results of a multicenter phase II study

Oncology

Volumn 68, Issue 1, 2005, Pages 58-63

  Aparicio, Jorge ^a   Vicent, José M ^b   Maestu, Inmaculada ^c   Bosch, Carles ^d   Galán, Antonio ^e   Busquier, Isabel ^f   Llorca, Cristina ^g   Garcerá, Salvador ^h   Campos, Juan M ⁱ   López Tendero, Pedro ^a   Balcells, Miquel ^j  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e HOSPITAL DE SAGUNTO   (Spain)

^f Hospital Provincial   (Spain)

^g Hospital General   (Spain)

^h HOSPITAL DE LA RIBERA   (Spain)

ⁱ HOSPITAL ARNAU DE VILANOVA   (Spain)

^j Prasfarma SA   (Spain)

more..

Author keywords

First line; Irinotecan; Metastatic colorectal cancer; Phase II; Raltitrexed

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; RALTITREXED; ANTINEOPLASTIC ANTIMETABOLITE; CAMPTOTHECIN; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CHOLINERGIC SYNDROME; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUTROPENIA; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME; VOMITING;

EID: 20944442973     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084821     Document Type: Article

References (24)

1. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
2. de Gramont A, Figer A, Seymur M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
3. Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T: Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer: A review of phase II/III trials. Eur J Cancer 2002;38:478-486.
4. Twelves C: The Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials. Eur J Cancer 2002;38:S15-S20.
5. Scheithauer W, Kornek GV, Ulrich-Pur H, Penz M, Raderer M, Salek T, Haider K, Kwasny W, Depisch D: Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: Results of a phase I-II trial. Cancer 2001;91:1264-1271.
6. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zamboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R: Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol 2002;13:716-720.
7. Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T, Raoul JL, Becouarn Y, Bertheault-Cvitkovic F, Ychou M, Nasca S, Fandi A, Barthelemy P, Douillard JY: Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol 2002;13:1072-1079.
8. Neri B, Doni L, Fulignati C, Perfetto F, Turrini M, Andreoli F, Pantalone D, Pernice LM, Taruffi F, Martini V, Poma A, Valeri A, Bacci G, Sancez L, Moretti R: Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: A multicentric phase II trial. Anticancer Drugs 2002;13:719-724.
9. Ford HER, Cunningham D, Ross PJ, Rao S, Aherne GW, Benepal TS, Price T, Massey A, Vernillet L, Gruia G: Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. Br J Cancer 2000;83:146-152.
10. Stevenson JP, Redlinger M, Kluijtmans LAJ, Sun W, Algazy K, Giantonio B, Haller DG, Hardy C, Whitehead AS, O'Dwyer PJ: Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. J Clin Oncol 2001;19:4081-4087.
11. Aparicio J, de las Peñas R, Vicent JM, Garcerá S, Llorca C, Maestu I, Yuste AL, Farrés J: Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory, advanced colorectal cancer. Oncology 2002;63:42-47.
12. Aparicio J, Vicent JM, Maestu I, Garcerá S, Busquier I, Bosch C, Llorca C, Díaz R, Fernández-Martos C, Galán A: Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol 2003;14:1121-1125.
13. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A: Irinotecan and raltitrexed: An active combination in advanced colorectal cancer. Ann Oncol 2002;13:1424-1429.
14. Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, López de Tejada MR, Rodríguez- García JM, Martínez MP, Sanz Martín M, Sánchez JJ, González Barón M: Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: A phase II study. Br J Cancer 2004;90:1502-1507.
15. Cancer Therapy Evaluation Program: Common toxicity criteria, version 2.0. Bethesda, National Cancer Institute, 1998.
16. Wadler S, Benson III AB, Englelking C, Catalano R, Field M, Kornblau SM, Mitchell E, Rubin J, Trotta P, Vokes E: Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 1998;16: 3169-3178.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
18. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Coutinho AK, Rocha Lima CMS: Metastatic colorectal cancer: Systemic treatment in the new millenium. Cancer Control 2003;10:224-238.
20. Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B: Raltitrexed: Current clinical status and future directions. Ann Oncol 2002;13:513-522.
21. Feliu J, Mel JR, Camps C, Escudero P, Aparicio J, Menéndez D, García Girón C, Rodríguez MR, Sánchez JJ, González Barón M: Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: An active and low toxicity regimen. Eur J Cancer 2002;38:1204-1211.
22. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
23. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR: Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 1998;4:1323-1330.
24. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-237.